Literature DB >> 11604587

Mortality and causes of death in systemic lupus erythematosus.

J Trager1, M M Ward.   

Abstract

Cohort studies of survival in systemic lupus erythematosus (SLE) often have been limited by methodologic problems. In studies of inception cohorts of patients followed since 1980, survival at 5 years has exceeded 90%. These estimates are generally higher than survival estimates from earlier studies, suggesting that short-term survival in SLE has improved. There is less evidence to support major improvements over time in survival after 10 years or more of SLE. Infections, atherosclerotic disease, and active systemic lupus erythematosus or organ damage caused by SLE are the main causes of death in patients with SLE, but the proportion of early deaths caused by active SLE has decreased over time.

Entities:  

Mesh:

Year:  2001        PMID: 11604587     DOI: 10.1097/00002281-200109000-00002

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  78 in total

Review 1.  Infectious CNS disease as a differential diagnosis in systemic rheumatic diseases: three case reports and a review of the literature.

Authors:  K Warnatz; H H Peter; M Schumacher; L Wiese; A Prasse; F Petschner; P Vaith; B Volk; S M Weiner
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

2.  [Systemic lupus erythematosus].

Authors:  C Kneitz; M Goebeler; H P Tony
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

3.  Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus.

Authors:  Aimee O Hersh; Laura Trupin; Jinoos Yazdany; Peter Panopalis; Laura Julian; Patricia Katz; Lindsey A Criswell; Edward Yelin
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-08       Impact factor: 4.794

4.  Epicardial adipose tissue is increased in patients with systemic lupus erythematosus.

Authors:  Aliza Lipson; Nikolaos Alexopoulos; Gregory Randell Hartlage; Chesnal Arepalli; Annette Oeser; Aihua Bian; Tebeb Gebretsadik; Ayumi Shintani; Arthur E Stillman; C Michael Stein; Paolo Raggi
Journal:  Atherosclerosis       Date:  2012-06-17       Impact factor: 5.162

5.  Lupus: an overview of the disease and management options.

Authors:  William Maidhof; Olga Hilas
Journal:  P T       Date:  2012-04

Review 6.  [Glucocorticoid therapy in collagen diseases diseases].

Authors:  L Unger; M Kayser; M Enderlein; K Manger; H Nüsslein
Journal:  Z Rheumatol       Date:  2005-04       Impact factor: 1.372

Review 7.  [Early diagnosis in patients with systemic lupus erythematosus (SLE)].

Authors:  M Gaubitz; H Schotte
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

8.  Administration of activated lymphocyte-derived DNA accelerates and aggravates lupus nephritis in B6/lpr mice: a new approach to modify a lupus murine model.

Authors:  Y Zhu; Y Yue; S Xiong
Journal:  Clin Exp Immunol       Date:  2018-07-23       Impact factor: 4.330

9.  Stress Intervention and Disease in African American Lupus Patients: The Balancing Lupus Experiences with Stress Strategies (BLESS) Study.

Authors:  Edith M Williams; Diane Kamen; Megan Penfield; James C Oates
Journal:  Health (Irvine Calif)       Date:  2014-01

10.  Ethnic disparities among patients with systemic lupus erythematosus in South Carolina.

Authors:  Erica Anderson; Paul J Nietert; Diane L Kamen; Gary S Gilkeson
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.